James Edinger

Dr. Edinger has served as Vice President of Preclinical Sciences since September 2019. In this capacity, he oversees Mustang’s Research, Translational, Analytical, and Process Development activities. Prior to Mustang, Dr. Edinger was Senior Director of Integrative Research and Strategy at Celularity, focused on scientific oversight of Intellectual Property, Research, Translational, and Process Development in a matrixed environment, as well as driving scientific due diligence of external opportunities. Research efforts focused on developing products in several areas of cellular therapeutics, including placental mesenchymal stem cells, T cells, NK cells, CAR-T cells, CAR-NK cells, and genetic modifications thereof. He previously served as Director of Research Strategy and Innovation at Celgene Cellular Therapeutics, leading Intellectual Property, Research, Translational, and Process Development for an autologous HPV antigen-specific T cell product in early development. His early career included academic appointments at Columbia University and Hunter College of CUNY, developing research programs in mouse and human immunology. Dr. Edinger holds a Ph.D. in Biochemistry/Chemistry from the University of Maryland, Baltimore County, and he completed his postdoctoral research at Weill Cornell Medical College in New York City.